2R2 SOP17_01Sep2022

Title SOP Code Effective Date

Closing participant files

2R2 SOP17_01Sep2022 26 Sep 2022

- VIII. Participant file: A participant file refers to all documents which purpose is to record specifically research-related information about a participant. These documents include case report forms (CRFs), as well as documents that are site-specific. A participant file does not include source documents that need to remain in a patient s chart after the conclusion of a study.
- IX. **Participant file closure**: Participant file closure refers to the process by which a participant file is reviewed, cleaned, and archived once a participant has completed every phase of the study. Once closed, a participant file should not undergo any change.

5.0 Procedures

5.1 General information

- ∉ A participant file should be closed as soon as possible after follow-up period has been completed (i.e. when post-treatment follow-up is completed, 26 months post-randomisation);
- ∉ Study sites must develop operational and staffing plans for completion of all required procedures listed in this SOP;
- # The use of liquid corrector or correcting material is prohibited when making modifications to a participant file. Modification must be clearly visible, be dated and signed by the person doing the modification.

5.2 Reviewing and cleaning the participant file

Once a participant s follow-up period is completed (i.e. 26 months post-randomisation), site investigator should ensure the integrity and coherence of the collected information by reviewing and cleaning the participant file:

- For each participant, an authorized person, as documented in the task delegation of responsibilities form (refer to SOP1), reviews the participant file by adhering to the following procedures:
 - a) If not already done, put all documents pertaining to a participant file into one file folder (except the participant identification form and the consent form);
 - b) Attach the applicable study file closure labels on the outside of the file folder. Note: all files will have Label 1- FOR ALL FILES (refer to Appendix 1 for a sample of labels). Other labels (see Appendix 1), will be applied as needed, in particular: files of participants with Adverse events reports (CRF9, CRF10) will have also Label 2- Adverse Events; files of participants with active TB reports (CRF11-12) will have Label 3-Active TB, files of participants who died (at any point during the study), will have Label 4-Death; files of participants who participated in PK sampling (CRF13), will have Label 5-PK.
 - c) When a section of the participant file has been reviewed, indicate this on the appropriate area of the label (i.e. indicate YES/NO/NA);
 - d) For Indonesia and Vietnam sites: ensure that all necessary paper copies of Source

SOP017_01Sep2022	26Sep2022	NA (original version)

APPENDIX 1

LABELS FOR CLOSING STUDY PARTICIPANT FILES

(1) FOR ALL FILES

Reviewed: Screening & ran	ndomization	CRF: source	e doc:
Follow-up durin	ng treatment	CRF: source	e doc:
End of treatment CRF:		_	
Follow-up post treatmen	nt CRF:	source doc:	NA:
Adverse Events CRF:	NA:	source doc:	NA:
Active TB CRF:	NA:	source doc:	NA:
Subject file FULLY anonyn	nized:		
Consent stored separatel	y:		
Identification form store	d separately	:	
Subject file ready for archiv	ving:		
Date of file closure _	/	/	

(2) FOR ADVERSE EVENTS

ADVERSE EVENT Date of ADVERSE EVENT ____/____/_____ TYPE: GRADE: 1 2 3 4 5 RELATIONSHIP: Unlikely Possible Probable

(3) FOR ACTIVE TB (ATB)

Active TB Patient

Diagnosis: ATB Clinical	ATB Microbiological	Not TB
If ATB, Date of DIAGNOSIS	///	
If ATB, Date of tx started	///	
If ATB, Date of conversion	///	or N/A

(4) FOR DEATH

DEATH

Date of death / /	·
Death in: treatment phase	post-treatment phase
If in treatment phase, relationship: Unlik	ely Possible Probable

Sample shipped: Box A only All samples